AstraZeneca Total Operating Expenses vs Research Development Analysis

AZN Stock

10,938 94.00 0.87%

AstraZeneca PLC financial indicator trend analysis is way more than just evaluating AstraZeneca PLC prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AstraZeneca PLC is a good investment. Please check the relationship between AstraZeneca PLC Total Operating Expenses and its Research Development accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Total Operating Expenses vs Research Development

Total Operating Expenses vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AstraZeneca PLC Total Operating Expenses account and Research Development. At this time, the significance of the direction appears to have almost identical trend.

The correlation between AstraZeneca PLC's Total Operating Expenses and Research Development is 0.98. Overlapping area represents the amount of variation of Total Operating Expenses that can explain the historical movement of Research Development in the same time period over historical financial statements of AstraZeneca PLC, assuming nothing else is changed. The correlation between historical values of AstraZeneca PLC's Total Operating Expenses and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Operating Expenses of AstraZeneca PLC are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Total Operating Expenses i.e., AstraZeneca PLC's Total Operating Expenses and Research Development go up and down completely randomly.

Correlation Coefficient

0.98

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Research Development

Most indicators from AstraZeneca PLC's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AstraZeneca PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

The current year's Tax Provision is expected to grow to about 1.1 B, whereas Selling General Administrative is forecasted to decline to about 215.2 M.

	2022	2023	2024	2025 (projected)
Interest Expense	1.3B	1.6B	1.8B	1.9B
Depreciation And Amortization	5.3B	4.9B	5.7B	6.0B

Interest Expense Depreciation And Amortization

AstraZeneca PLC fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Other Assets	Common Stock Total Equity
Total Assets		0.96	0.93	0.96	0.93	0.81	0.43	0.88	-0.25	0.08	0.31	0.99	0.64	0.15	0.78	0.88	-0.4	0.86	0.87	0.27	0.97	0.87	0.7	0.88	0.9	0.25
Short Long Term Debt Total	0.96		0.95	0.91	0.83	0.82	0.58	0.98	-0.5	-0.09	0.11	0.97	0.5	-0.07	0.62	0.79	-0.52	0.9	0.91	0.1	0.97	0.85	0.57	0.87	0.89	0.2
Other Current Liab	0.93	0.95		0.94	0.79	0.78	0.53	0.9	-0.39	-0.2	0.19	0.95	0.57	-0.05	0.6	0.79	-0.63	0.85	0.81	0.04	0.95	0.89	0.53	0.85	0.9	0.16
Total Current Liabilities	0.96	0.91	0.94		0.91	0.76	0.46	0.83	-0.2	0.12	0.31	0.95	0.76	0.17	0.83	0.88	-0.37	0.75	0.77	0.29	0.93	0.94	0.66	0.93	0.85	0.17
Total Stockholder Equity	0.93	0.83	0.79	0.91		0.67	0.37	0.73	-0.08	0.25	0.38	0.89	0.7	0.25	0.9	0.84	-0.29	0.62	0.79	0.47	0.81	0.83	0.75	0.85	0.75	0.12
Property Plant And Equipment Net	0.81	0.82	0.78	0.76	0.67		0.46	0.76	-0.38	0.06	0.37	0.81	0.39	0.18	0.54	0.89	-0.32	0.8	0.75	0.21	0.84	0.65	0.8	0.68	0.81	0.49
Current Deferred Revenue	0.43	0.58	0.53	0.46	0.37	0.46		0.61	-0.69	-0.17	-0.13	0.42	0.1	-0.25	0.26	0.29	-0.4	0.37	0.62	0.09	0.44	0.5	0.27	0.49	0.45	-0.03
Net Debt	0.88	0.98	0.9	0.83	0.73	0.76	0.61		-0.64	-0.18	-0.11	0.92	0.43	-0.28	0.49	0.69	-0.55	0.88	0.89	-0.02	0.91	0.81	0.43	0.83	0.81	0.1
Retained Earnings	-0.25	-0.5	-0.39	-0.2	-0.08	-0.38	-0.69	-0.64		0.49	0.54	-0.34	0.24	0.7	0.2	-0.07	0.56	-0.44	-0.5	0.49	-0.35	-0.23	0.08	-0.36	-0.32	0.05
Accounts Payable	0.08	-0.09	-0.2	0.12	0.25	0.06	-0.17	-0.18	0.49		0.38	-0.02	0.45	0.65	0.57	0.29	0.78	-0.19	-0.05	0.7	-0.05	0.08	0.46	0.08	-0.09	0.18
Cash	0.31	0.11	0.19	0.31	0.38	0.37	-0.13	-0.11	0.54	0.38		0.21	0.22	0.91	0.51	0.54	0.15	0.15	0.09	0.51	0.24	0.09	0.73	0.12	0.36	0.58
Non Current Assets Total	0.99	0.97	0.95	0.95	0.89	0.81	0.42	0.92	-0.34	-0.02	0.21		0.59	0.04	0.7	0.85	-0.47	0.89	0.87	0.16	0.98	0.86	0.63	0.88	0.9	0.23
Non Currrent Assets Other	0.64	0.5	0.57	0.76	0.7	0.39	0.1	0.43	0.24	0.45	0.22	0.59		0.28	0.82	0.65	0.06	0.29	0.36	0.45	0.54	0.83	0.46	0.66	0.43	-0.12
Cash And Short Term Investments	0.15	-0.07	-0.05	0.17	0.25	0.18	-0.25	-0.28	0.7	0.65	0.91	0.04	0.28		0.51	0.42	0.53	-0.04	-0.09	0.65	0.06	-0.03	0.62	0.01	0.15	0.53
Net Receivables	0.78	0.62	0.6	0.83	0.9	0.54	0.26	0.49	0.2	0.57	0.51	0.7	0.82	0.51		0.81	0.06	0.38	0.55	0.69	0.63	0.76	0.76	0.75	0.56	0.14
Common Stock Shares Outstanding	0.88	0.79	0.79	0.88	0.84	0.89	0.29	0.69	-0.07	0.29	0.54	0.85	0.65	0.42	0.81		-0.15	0.71	0.64	0.44	0.84	0.74	0.87	0.8	0.77	0.41
Short Term Investments	-0.4	-0.52	-0.63	-0.37	-0.29	-0.32	-0.4	-0.55	0.56	0.78	0.15	-0.47	0.06	0.53	0.06	-0.15		-0.48	-0.49	0.48	-0.46	-0.4	0.0	-0.37	-0.48	0.16
Non Current Liabilities Total	0.86	0.9	0.85	0.75	0.62	0.8	0.37	0.88	-0.44	-0.19	0.15	0.89	0.29	-0.04	0.38	0.71	-0.48		0.82	-0.08	0.95	0.63	0.48	0.65	0.89	0.41
Inventory	0.87	0.91	0.81	0.77	0.79	0.75	0.62	0.89	-0.5	-0.05	0.09	0.87	0.36	-0.09	0.55	0.64	-0.49	0.82		0.15	0.85	0.73	0.59	0.69	0.85	0.16
Other Current Assets	0.27	0.1	0.04	0.29	0.47	0.21	0.09	-0.02	0.49	0.7	0.51	0.16	0.45	0.65	0.69	0.44	0.48	-0.08	0.15		0.1	0.26	0.6	0.21	0.04	0.14
Total Liab	0.97	0.97	0.95	0.93	0.81	0.84	0.44	0.91	-0.35	-0.05	0.24	0.98	0.54	0.06	0.63	0.84	-0.46	0.95	0.85	0.1		0.83	0.6	0.83	0.93	0.32
Property Plant And Equipment Gross	0.87	0.85	0.89	0.94	0.83	0.65	0.5	0.81	-0.23	0.08	0.09	0.86	0.83	-0.03	0.76	0.74	-0.4	0.63	0.73	0.26	0.83		0.5	0.86	0.71	-0.09
Total Current Assets	0.7	0.57	0.53	0.66	0.75	0.8	0.27	0.43	0.08	0.46	0.73	0.63	0.46	0.62	0.76	0.87	0.0	0.48	0.59	0.6	0.6	0.5		0.54	0.64	0.51
Short Term Debt	0.88	0.87	0.85	0.93	0.85	0.68	0.49	0.83	-0.36	0.08	0.12	0.88	0.66	0.01	0.75	0.8	-0.37	0.65	0.69	0.21	0.83	0.86	0.54		0.73	0.07
Other Assets	0.9	0.89	0.9	0.85	0.75	0.81	0.45	0.81	-0.32	-0.09	0.36	0.9	0.43	0.15	0.56	0.77	-0.48	0.89	0.85	0.04	0.93	0.71	0.64	0.73		0.4
Common Stock Total Equity	0.25	0.2	0.16	0.17	0.12	0.49	-0.03	0.1	0.05	0.18	0.58	0.23	-0.12	0.53	0.14	0.41	0.16	0.41	0.16	0.14	0.32	-0.09	0.51	0.07	0.4

Click cells to compare fundamentals

AstraZeneca PLC Account Relationship Matchups

AstraZeneca PLC fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	66.7B	105.4B	96.5B	101.1B	116.3B	122.1B
Short Long Term Debt Total	20.4B	30.8B	29.2B	28.6B	32.9B	34.6B
Other Current Liab	14.4B	16.0B	16.3B	19.8B	22.8B	23.9B
Total Current Liabilities	20.3B	22.6B	26.3B	30.5B	35.1B	36.9B
Total Stockholder Equity	15.6B	39.3B	37.0B	39.1B	45.0B	47.3B
Property Plant And Equipment Net	8.9B	10.2B	9.4B	10.5B	12.1B	6.8B
Net Debt	12.5B	24.5B	23.1B	22.8B	26.2B	27.5B
Retained Earnings	5.3B	1.7B	(574M)	4.5B	5.2B	8.5B
Accounts Payable	2.4B	2.8B	2.6B	3.3B	3.8B	2.8B
Cash	7.8B	6.3B	6.2B	5.8B	6.7B	4.7B
Non Current Assets Total	47.2B	79.1B	73.9B	76.1B	87.5B	91.8B
Non Currrent Assets Other	1.1B	1.1B	1.1B	5.6B	6.5B	6.8B
Cash And Short Term Investments	8.0B	6.4B	6.4B	5.9B	6.7B	5.8B
Net Receivables	3.8B	6.0B	7.2B	8.4B	9.7B	10.2B
Common Stock Shares Outstanding	1.3B	1.4B	1.6B	1.6B	1.8B	1.4B
Short Term Investments	160M	69M	239M	20M	18M	17.1M
Liabilities And Stockholders Equity	66.7B	105.4B	96.5B	101.1B	116.3B	122.1B
Non Current Liabilities Total	30.8B	43.5B	33.1B	31.4B	36.1B	37.9B
Inventory	4.0B	9.0B	4.7B	5.4B	6.2B	6.5B
Other Current Assets	3.7B	4.8B	4.4B	5.4B	6.2B	5.2B
Total Liab	51.1B	66.1B	59.4B	62.0B	71.2B	74.8B
Property Plant And Equipment Gross	8.9B	10.2B	9.4B	19.1B	22.0B	23.1B
Total Current Assets	19.5B	26.2B	22.6B	25.1B	28.8B	15.3B
Short Term Debt	2.4B	2.9B	6.5B	5.4B	6.2B	6.5B
Other Assets	3.5B	4.3B	5.3B	4.2B	4.8B	5.0B
Other Stockholder Equity	8.0B	35.1B	33.5B	33.3B	38.3B	40.2B
Accumulated Other Comprehensive Income	881M	111M	(1.6B)	(949M)	(1.1B)	(1.1B)
Intangible Assets	20.9B	42.4B	39.3B	38.1B	43.8B	46.0B
Other Liab	10.3B	10.5B	13.0B	8.5B	9.8B	6.7B
Long Term Debt	17.5B	28.1B	23.0B	22.4B	25.7B	27.0B
Good Will	11.8B	20.0B	19.8B	20.0B	23.1B	24.2B
Property Plant Equipment	8.3B	8.9B	10.2B	9.4B	10.9B	7.9B
Net Tangible Assets	(19.4B)	(17.2B)	(23.1B)	(22.1B)	(19.9B)	(20.9B)
Short Long Term Debt	2.2B	1.7B	5.3B	5.1B	5.9B	6.2B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Other Information on Investing in AstraZeneca Stock

Balance Sheet is a snapshot of the financial position of AstraZeneca PLC at a specified time, usually calculated after every quarter, six months, or one year. AstraZeneca PLC Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of AstraZeneca PLC and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which AstraZeneca currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AstraZeneca Total Operating Expenses vs Research Development Analysis

Total Operating Expenses vs Research Development

Total Operating Expenses vs Research Development Correlation Analysis

Correlation Coefficient

Total Operating Expenses

Research Development

AstraZeneca PLC fundamental ratios Correlations

AstraZeneca PLC Account Relationship Matchups

High Positive Relationship

High Negative Relationship

AstraZeneca PLC fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in AstraZeneca Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 0.99	Total Assets
Net Debt	+ 0.98	Short Long Term Debt Total
Total Liab	+ 0.98	Non Current Assets Total
Total Liab	+ 0.97	Total Assets
Non Current Assets Total	+ 0.97	Short Long Term Debt Total
Total Liab	+ 0.97	Short Long Term Debt Total

Retained Earnings	- 0.69	Current Deferred Revenue
Retained Earnings	- 0.64	Net Debt
Short Term Investments	- 0.63	Other Current Liab
Short Term Investments	- 0.55	Net Debt
Short Term Investments	- 0.52	Short Long Term Debt Total
Inventory	- 0.5	Retained Earnings